welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy
study id #: NCT02369731
condition: Duchenne Muscular Dystrophy
This study is being performed as a post-approval safety study (PASS), per the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), to gather data on Translarna (ataluren) safety, effectiveness, and prescription patterns in routine clinical practice.
mechanism of action: Exon-skipping to promote dystrophin production
last updated: October 21, 2020
start date: April 30, 2015
estimated completion: May 30, 2025
phase of development: N/A
size / enrollment: 270
This is a multicenter, observational study of participants receiving Translarna based on inclusion of their data in a registry. This study is intended to enroll 270 participants across ~50 care centers in Europe and other regions over a period of ~ 2 years. The study population will include participants who are receiving usual care treatment with commercial supply of Translarna (or receiving care within a named participant early access program) and who provide consent. Participants will be followed for at least 5 years from their date of enrollment. Safety and efficacy data will be collected in conjunction with routine visits conducted as per usual care. Although there are no protocol-mandated procedures, it is expected that physicians and other caregivers will follow published treatment guidelines and standards of care.
- Percentage of Participants With Adverse Events [ Time Frame: 5 years ]
- Prescriber and Participant Compliance With Prescribing Information According to the Approved Labelling [ Time Frame: 5 years ]
• Eligible Sexes: all
• Willing to provide written informed consent to allow the study data collection procedures (either by the participant or through authorisation by a legal guardian)
• Participants who are receiving ataluren or placebo in a blinded, randomized clinical trial, or ataluren in any other ataluren clinical trial or cohort early access program that prevents participation in this study
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneThis guidance is not intended to affect ...
Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystroph...Objective: Examine the safety/tolerabil...
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pa...
A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)This study is designed to evaluate the a...
A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From >=6 Months to <2 Years of Age W...This study is designed to evaluate safet...
Ataluren Confirmatory Trial in DMD: Effect of Ataluren on Activities of Daily Living in Nonsense Mutation Duchenne M...Objective: Evaluate the effect of atalu...
Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and CanadaDuchenne/Becker muscular dystrophy (DBMD...
New Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology...PTC Therapeutics, Inc. today announced t...